Medium-Dose Chronic Cannabidiol Treatment Reverses Object Recognition Memory Deficits of APP Swe /PS1ΔE9 Transgenic Female Mice.
Alzheimer’s disease (AD) is a neurodegenerative disease that causes behavioral and cognitive impairments. The phytocannabinoid cannabidiol (CBD) has anti-inflammatory, antioxidant, and neuroprotective properties, and in vitro and limited in vivo evidence suggests that CBD possesses therapeutic-like properties for the treatment of AD. Cannabinoids are known to have dose-dependent effects and the therapeutic potential of medium-dose CBD for AD transgenic mice has not been assessed in great detail yet. 12-month-old control and APP Swe/PS1ΔE9 (APPxPS1) transgenic female mice were treated daily via intraperitoneal injection with 5 mg/kg bodyweight CBD (or vehicle) commencing three weeks prior to the assessment of behavioral domains including anxiety, exploration, locomotion, motor functions, cognition, and sensorimotor gating. APPxPS1 mice exhibited a hyperlocomotive and anxiogenic-like phenotype and had wild type-like motor and spatial learning abilities, although AD transgenic mice took generally longer to complete the cheeseboard training (due to a lower locomotion speed). Furthermore spatial learning and reversal learning was delayed by one day in APPxPS1 mice compared to control mice. All mice displayed intact spatial memory and retrieval memory, but APPxPS1 mice showed reduced levels of perseverance in the cheeseboard probe trial. Importantly, vehicle-treated APPxPS1 mice were characterized by object recognition deficits and delayed spatial learning, which were reversed by CBD treatment. Finally, impairments in sensorimotor gating of APPxPS1 mice were not affected by CBD. In conclusion, medium-dose CBD appears to have therapeutic value for the treatment of particular behavioral impairments present in AD patients. Future research should consider the molecular mechanisms behind CBD’s beneficial properties for AD transgenic mice.
Keywords: APPSwe/PS1ΔE9; Alzheimer’s disease; behavior; cannabidiol; transgenic mouse model; treatment.
Copyright © 2020 Coles, Watt, Kreilaus and Karl.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Novel behavioural characteristics of female APPSwe/PS1ΔE9 double transgenic mice.
Behav Brain Res. 2014 Mar 1;260:111-8. doi: 10.1016/j.bbr.2013.11.046. Epub 2013 Dec 4. Behav Brain Res. 2014. PMID: 24315833
Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice.
Psychopharmacology (Berl). 2014 Aug;231(15):3009-17. doi: 10.1007/s00213-014-3478-5. Epub 2014 Mar 1. Psychopharmacology (Berl). 2014. PMID: 24577515
Chronic Treatment with 50 mg/kg Cannabidiol Improves Cognition and Moderately Reduces Aβ40 Levels in 12-Month-Old Male AβPPswe/PS1ΔE9 Transgenic Mice.
J Alzheimers Dis. 2020;74(3):937-950. doi: 10.3233/JAD-191242. J Alzheimers Dis. 2020. PMID: 32116258
In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer’s Disease.
Front Pharmacol. 2017 Feb 3;8:20. doi: 10.3389/fphar.2017.00020. eCollection 2017. Front Pharmacol. 2017. PMID: 28217094 Free PMC article. Review.
The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer’s disease.
Behav Pharmacol. 2017 Apr;28(2 and 3-Spec Issue):142-160. doi: 10.1097/FBP.0000000000000247. Behav Pharmacol. 2017. PMID: 27471947 Review.
- Arendash G. W., King D. L., Gordon M. N., Morgan D., Hatcher J. M., Hope C. E., et al. (2001). Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res. 891 (1), 42–53. 10.1016/S0006-8993(00)03186-3 – DOI – PubMed